The Emergence of NK Cell-Based Treatment in Cancer Immunotherapy

By Olivier Lucar
August 20, 2019

The 2018 Nobel Prize in Physiology or Medicine was awarded to James Alison and Tasuku Honjo for their groundbreaking work on cancer therapy targeting the inhibition of immune checkpoints (IC), proteins that negatively regulate the immune response. Their work was groundbreaking because it opened a new powerful tool for the cure of cancer—immunotherapy (Fritz J. et Lenardo M., 2019).

The Cancer Revolution

At the beginning of cancer research, the immune system was not considered an important actor in cancer pathogenesis. But, in fact, the tumor microenvironment is Continue reading “The Emergence of NK Cell-Based Treatment in Cancer Immunotherapy”

How CAR-T Cell Therapy is Impacting Solid Tumor Cancer Research

By David Haas
Wednesday June 5, 2019

Treatment options available to cancer patients have both improved and grown over the past decade. The development of personalized medicine has enabled patients to seek a new route, tailoring their treatments specifically to their situations. One outcome of this unique treatment approach is the development of CAR-T (chimeric antigen receptor T) cell therapy (see: Taking Personalized Medicine to a New Level: CAR-T Cell Therapy). Continue reading “How CAR-T Cell Therapy is Impacting Solid Tumor Cancer Research”

Taking Personalized Medicine to a New Level: CAR-T Cell Therapy

By Martina McGrath, MD
September 13, 2017

Each individual is estimated to have around 4 x 1011 T cells, comprising many millions of T cell clones,1 each randomly produced in the thymus with a unique T cell receptor (TCR) specific for a given antigen. This massive diversity in T cell repertoire gives our immune systems the capacity to protect against the incredible array of bacteria, viruses and fungi that assail us on a constant basis. Continue reading “Taking Personalized Medicine to a New Level: CAR-T Cell Therapy”

Inclisiran: A Novel Therapeutic for Long-Term Lowering of LDL Cholesterol?

By Connor Emdin
May 18, 2017

Elevated low-density lipoprotein cholesterol (LDL cholesterol) is a leading cause of coronary heart disease and death worldwide.1 When LDL cholesterol particles become oxidized, they can invade the endothelium of blood vessels and attract macrophages, forming atherosclerotic plaques. Over a lifetime, high levels of LDL cholesterol can lead to the formation of numerous unstable atherosclerotic plaques, potentially leading to myocardial infarction, stroke, and death from cardiovascular disease (CVD).2 Continue reading “Inclisiran: A Novel Therapeutic for Long-Term Lowering of LDL Cholesterol?”

Hep C Positive Kidneys into Hep C Negative Patients: Pushing the Boundaries of Transplantation

[Photo by Bill Branson, NIH Medical Arts, National Institutes of Health. Pictured are Robert Colbert, M.D., Ph.D., Amy Petrik, Ph.D., and Grace Kwon, Ph.D. ]

By Martina M. McGrath, MD
May 4, 2017

Currently, over 97,000 patients are awaiting kidney transplant.1 Hepatitis C (HCV) infection is prevalent in the community, and it has been reported that >3000 kidneys from HCV+ donors were offered between 2005 and 2014.2 Prior to the current era of direct-acting antiviral agents (DAAV), patients with HCV who underwent renal transplantation had poorer outcomes, and antiviral treatment with interferon was associated with increased risk of rejection. Likely related to these risks, it has been reported that over 500 kidneys from HCV+ donors are discarded annually.2 However, DAAVs have transformed the management of HCV infection. Greater than 90 percent cure rates have been reported with many of these medications, which are generally well-tolerated. With the availability of safe and effective antiviral therapy for HCV, the question has arisen, could these kidneys now be safely used in HCV-negative recipients? Continue reading “Hep C Positive Kidneys into Hep C Negative Patients: Pushing the Boundaries of Transplantation”

The Artificial Pancreas: A Breakthrough in Diabetes Management

Ajay K. Singh, MBBS, FRCP, MBA
January 3, 2017

The discovery of insulin was one of the biggest discoveries in medicine. In January 1922 (thought to be January 11), Dr. Frederick G. Banting and his student assistant, Mr. Charles Best, chose 14-year-old Leonard Thompson as the first person with diabetes to receive insulin. In doing so, they saved Leonard’s life and thus began an era where diabetes mellitus, a hitherto fatal disease, could be treated successfully. Continue reading “The Artificial Pancreas: A Breakthrough in Diabetes Management”

Two Promising New Diabetes Drugs

Reducing cardiovascular complications in patients with diabetes: exciting new drug therapy on the horizon.

By Ajay K. Singh, MBBS, FRCP, MBA
December 7, 2016

Diabetes mellitus is in epidemic proportions in many parts of the world. Its most consequential and debilitating complications are cardiovascular disease, retinopathy, and nephropathy. Newer agents are now emerging and have the potential to transform the management of diabetes. Continue reading “Two Promising New Diabetes Drugs”